Clinical Trials
18 trialsNCT04401059 2023-12-27
SELECT-2
Hangzhou Normal University
Phase 4 Unknown
NCT05430386 2023-02-14
Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT02981108 2023-01-23
A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1/2 Unknown
NCT03849768 2023-01-20
A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 3 Unknown
NCT05662813 2022-12-23
Almonertinib Therapy in Patients With Abnormal Liver Function After EGFR-TKI Treatment, or Almonertinib First-line Therapy in Patients With Basic Hepatopathy
West China Hospital
Phase 2 Unknown
NCT05223595 2022-02-04
A Study of Gentuximab in Combination With Almonertinib in EGFR Mutation-positive Metastatic NSCLC
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT04755738 2021-09-05
MWA
Qianfoshan Hospital
Phase 2 Unknown
NCT04978753 2021-07-27
the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung Cancer
Sun Yat-sen University
Phase 2 Unknown
NCT04951648 2021-07-07
A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 3 Unknown
NCT04952168 2021-07-07
Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC
Tongji Hospital
Phase 2 Unknown
NCT04944069 2021-06-29
ATTRACT
Second Affiliated Hospital of Nanchang University
Phase NA Unknown
NCT04905550 2021-06-02
Almonertinib Combined With Cerebral Radiation Treat Brain Metastases From EGFR Positive NSCLC
Chongqing University Cancer Hospital
Phase 2 Unknown
NCT04636593 2021-01-12
A Phase 2 Trial of Almonertinib With Concurrent Radiotherapy in The Treatment of Local Advanced EGFR-mutant NSCLC
First People's Hospital of Hangzhou
Phase 2 Unknown
NCT04592666 2020-10-19
APPEAL
Fudan University
Phase 2 Unknown
NCT04553887 2020-10-14
AUTUMN
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT04500704 2020-08-05
ACROSS1
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3 Unknown
NCT04500717 2020-08-05
ACROSS2
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3 Unknown
NCT04455594 2020-07-02
ANSWER
The First Affiliated Hospital of Guangzhou Medical University
Phase 2 Unknown